Us Bancorp \De\ Viking Therapeutics, Inc. Transaction History

Us Bancorp \De\

$82.9 Billion
Q3 2025

A detailed history of Us Bancorp \De\ transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Us Bancorp \De\ holds 10,453 shares of VKTX stock, worth $416,029. This represents 0.0% of its overall portfolio holdings.

Number of Shares

10,453

Previous 5,377 94.4%

Holding current value

$416,029

Previous $142,000 87.32%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 10, 2025	BUY	$23.09 - $42.09 $117,204 - $213,648	5,076 Added 94.4%	10,453 $266,000
Q2 2025 Jul 23, 2025	BUY	$19.98 - $29.49 $11,668 - $17,222	584 Added 12.18%	5,377 $142,000
Q1 2025 May 08, 2025	BUY	$24.15 - $42.89 $23,473 - $41,689	972 Added 25.44%	4,793 $115,000
Q4 2024 Feb 05, 2025	BUY	$38.28 - $78.03 $344 - $702	9 Added 0.24%	3,821 $153,000
Q3 2024 Oct 28, 2024	SELL	$49.84 - $70.47 $60,107 - $84,986	-1,206 Reduced 24.03%	3,812 $241,000

Q2 2024 Aug 06, 2024	SELL	$47.39 - $80.2 $91,178 - $154,304	-1,924 Reduced 27.72%	5,018 $266,000
Q1 2024 May 07, 2024	BUY	$17.4 - $94.5 $79,970 - $434,322	4,596 Added 195.91%	6,942 $569,000
Q4 2023 Feb 09, 2024	BUY	$9.24 - $19.64 $8,657 - $18,402	937 Added 66.5%	2,346 $43,000
Q3 2023 Nov 03, 2023	SELL	$10.92 - $16.0 $294,632 - $431,696	-26,981 Reduced 95.04%	1,409 $15,000
Q2 2023 Aug 09, 2023	SELL	$14.84 - $24.79 $87,244 - $145,740	-5,879 Reduced 17.16%	28,390 $460,000
Q1 2023 May 09, 2023	SELL	$8.08 - $17.33 $34,752 - $74,536	-4,301 Reduced 11.15%	34,269 $570,000
Q4 2022 Feb 13, 2023	BUY	$2.72 - $9.4 $104,910 - $362,558	38,570 New	38,570 $362,000
Q4 2021 Feb 11, 2022	SELL	$4.6 - $6.72 $21,445 - $31,328	-4,662 Closed	0 $0
Q3 2021 Nov 10, 2021	SELL	$5.58 - $7.04 $1,623 - $2,048	-291 Reduced 5.88%	4,662 $29,000
Q2 2021 Aug 05, 2021	SELL	$5.19 - $6.73 $254 - $329	-49 Reduced 0.98%	4,953 $30,000
Q1 2021 Apr 28, 2021	BUY	$5.74 - $9.67 $20,336 - $34,260	3,543 Added 242.84%	5,002 $32,000
Q4 2020 Feb 04, 2021	SELL	$5.3 - $6.71 $13,069 - $16,546	-2,466 Reduced 62.83%	1,459 $8,000
Q3 2020 Nov 10, 2020	SELL	$5.73 - $8.11 $1,203 - $1,703	-210 Reduced 5.08%	3,925 $23,000
Q2 2020 Aug 07, 2020	SELL	$4.35 - $8.08 $469 - $872	-108 Reduced 2.55%	4,135 $30,000
Q1 2020 May 13, 2020	BUY	$3.45 - $7.95 $724 - $1,669	210 Added 5.21%	4,243 $20,000
Q4 2019 Feb 04, 2020	BUY	$6.38 - $8.73 $293 - $401	46 Added 1.15%	4,033 $32,000
Q3 2019 Nov 08, 2019	SELL	$6.55 - $8.6 $707 - $928	-108 Reduced 2.64%	3,987 $27,000
Q2 2019 Aug 13, 2019	SELL	$7.67 - $10.63 $429 - $595	-56 Reduced 1.35%	4,095 $34,000
Q1 2019 May 08, 2019	BUY	$7.58 - $9.94 $31,464 - $41,260	4,151 New	4,151 $41,000

Others Institutions Holding VKTX

# of Institutions

433

Shares Held

66.6M

Call Options Held

7.21M

Put Options Held

3.87M

View Full List

About Viking Therapeutics, Inc.

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $3.05B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

More about VKTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

News

Stay updated on Us Bancorp \De\ with notifications on news.

Account